Dissection of PIM serine/threonine kinases in FLT3-ITD–induced leukemogenesis reveals PIM1 as regulator of CXCL12–CXCR4-mediated homing and migration
暂无分享,去创建一个
Stefan Knapp | Andrea Biondi | Antonello Villa | S. Knapp | A. Bullock | A. Villa | V. Pogačić | J. Schwaller | J. Duyster | A. Biondi | R. Grundler | C. Dierks | T. Dechow | Justus Duyster | Christine Dierks | G. Berridge | Alex N. Bullock | Tobias Dechow | Rebekka Grundler | Laurent Brault | Juerg Schwaller | Christelle Gasser | Sabine Woetzel | Vanda Pogacic | Sabine Ehret | Georgina Berridge | Anke Spoo | L. Brault | S. Ehret | C. Gasser | A. Spoo | Sabine Woetzel
[1] M. Nawijn,et al. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL. , 2006, Cancer research.
[2] P. Meltzer,et al. Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. , 2005, Blood.
[3] Kwang-Hoon Chun,et al. PKCδ modulates p21WAF1/CIP1 ability to bind to Cdk2 during TNFα-induced apoptosis , 2006 .
[4] R. Gorlin,et al. Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease , 2003, Nature Genetics.
[5] J. Juarez,et al. CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment , 2007, Leukemia.
[6] H. Kantarjian,et al. Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia. , 2005, Current molecular medicine.
[7] P. Koskinen,et al. Pim‐1 kinase promotes inactivation of the pro‐apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site , 2004, FEBS letters.
[8] T. Kipps,et al. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. , 2006, Blood.
[9] P. Klasse,et al. Chemokine receptor trafficking and viral replication , 1999, Immunological reviews.
[10] Stefan Knapp,et al. Structure and Substrate Specificity of the Pim-1 Kinase* , 2005, Journal of Biological Chemistry.
[11] M. Ratajczak,et al. The pleiotropic effects of the SDF-1–CXCR4 axis in organogenesis, regeneration and tumorigenesis , 2006, Leukemia.
[12] J. Field,et al. p21-activated Kinase 1 (Pak1)-dependent Phosphorylation of Raf-1 Regulates Its Mitochondrial Localization, Phosphorylation of BAD, and Bcl-2 Association* , 2005, Journal of Biological Chemistry.
[13] P. Hammerman,et al. Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival. , 2005, Blood.
[14] S. Knapp,et al. Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity. , 2007, Cancer research.
[15] Y. Chalandon,et al. Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies. , 2005, Haematologica.
[16] S. Koschmieder,et al. Pim2 complements Flt3 wild-type receptor in hematopoietic progenitor cell transformation , 2008, Leukemia.
[17] Chunaram Choudhary,et al. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. , 2003, Blood.
[18] Xunbin Wei,et al. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment , 2005, Nature.
[19] F. Sigaux,et al. The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[20] S. Knapp,et al. Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase. , 2005, Journal of medicinal chemistry.
[21] N. Magnuson,et al. Pim-1 Kinase-Dependent Phosphorylation of p21Cip1/WAF1 Regulates Its Stability and Cellular Localization in H1299 Cells , 2007, Molecular Cancer Research.
[22] R. Alon,et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. , 1999, Science.
[23] B. Löwenberg,et al. Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. , 2004, Blood.
[24] Kyu-Tae Kim,et al. Constitutively activated FLT3 phosphorylates BAD partially through Pim‐1 , 2006, British journal of haematology.
[25] N. Warrington,et al. Widespread CXCR4 activation in astrocytomas revealed by phospho-CXCR4-specific antibodies. , 2005, Cancer research.
[26] P. Laird,et al. Impaired interleukin-3 response in Pim-1-deficient bone marrow-derived mast cells. , 1993, Blood.
[27] C. Miething,et al. FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model. , 2005, Blood.
[28] Jos Jonkers,et al. Mice Deficient for All PIM Kinases Display Reduced Body Size and Impaired Responses to Hematopoietic Growth Factors , 2004, Molecular and Cellular Biology.
[29] C. Martínez-A,et al. Chemokines integrate JAK/STAT and G‐protein pathways during chemotaxis and calcium flux responses , 2003, European journal of immunology.
[30] E. Estey,et al. Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias , 2006, Molecular Cancer Therapeutics.
[31] J. Juarez,et al. SDF-1 and CXCR4 in normal and malignant hematopoiesis. , 2004, Histology and histopathology.
[32] M. Le Bousse-Kerdilès,et al. Stromal cell-derived factor 1 regulates primitive hematopoiesis by suppressing apoptosis and by promoting G(0)/G(1) transition in CD34(+) cells: evidence for an autocrine/paracrine mechanism. , 2002, Blood.
[33] Anton Berns,et al. High-throughput retroviral tagging to identify components of specific signaling pathways in cancer , 2002, Nature Genetics.
[34] A. Miyajima,et al. Suppression of interleukin‐3‐induced gene expression by a C‐terminal truncated Stat5: role of Stat5 in proliferation. , 1996, The EMBO journal.
[35] M. Lübbert,et al. CXCR4 is a prognostic marker in acute myelogenous leukemia. , 2007, Blood.
[36] Arnon Nagler,et al. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. , 2004, Cancer research.
[37] M. Loh,et al. Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. , 2000, Molecular cell.
[38] A. Allan,et al. Cancer stem cells: implications for the progression and treatment of metastatic disease , 2007, Journal of cellular and molecular medicine.
[39] H. Janssen,et al. Synaptotagmin 3 deficiency in T cells impairs recycling of the chemokine receptor CXCR4 and thereby inhibits CXCL12 chemokine-induced migration , 2007, Journal of Cell Science.
[40] J. Benovic,et al. Regulation of CXCR4 signaling. , 2007, Biochimica et biophysica acta.
[41] C. Peschel,et al. Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back , 2003, Leukemia.
[42] S. Mundell,et al. Trafficking of the HIV Coreceptor CXCR4 , 1999, The Journal of Biological Chemistry.
[43] G. Downey,et al. L-selectin stimulation enhances functional expression of surface CXCR4 in lymphocytes: implications for cellular activation during adhesion and migration. , 2003, Blood.